GB0322016D0 - New compounds - Google Patents

New compounds

Info

Publication number
GB0322016D0
GB0322016D0 GBGB0322016.7A GB0322016A GB0322016D0 GB 0322016 D0 GB0322016 D0 GB 0322016D0 GB 0322016 A GB0322016 A GB 0322016A GB 0322016 D0 GB0322016 D0 GB 0322016D0
Authority
GB
United Kingdom
Prior art keywords
new compounds
compounds
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0322016.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Original Assignee
Merck Sharp and Dohme Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd filed Critical Merck Sharp and Dohme Ltd
Priority to GBGB0322016.7A priority Critical patent/GB0322016D0/en
Publication of GB0322016D0 publication Critical patent/GB0322016D0/en
Priority to US10/571,544 priority patent/US20070078156A1/en
Priority to AU2004274230A priority patent/AU2004274230A1/en
Priority to EP04768514A priority patent/EP1675587A2/en
Priority to JP2006526691A priority patent/JP2007505877A/ja
Priority to CNA2004800271826A priority patent/CN1856304A/zh
Priority to PCT/GB2004/003968 priority patent/WO2005028445A2/en
Priority to CA002538454A priority patent/CA2538454A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
GBGB0322016.7A 2003-09-19 2003-09-19 New compounds Ceased GB0322016D0 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
GBGB0322016.7A GB0322016D0 (en) 2003-09-19 2003-09-19 New compounds
US10/571,544 US20070078156A1 (en) 2003-09-19 2004-09-16 Derivatives of n-(1h-indazolyl)-and n-(1h-indolyl)-urea as well as related compounds as modulators of the vanilloid-1 receptor (vr1) for treatment of pain
AU2004274230A AU2004274230A1 (en) 2003-09-19 2004-09-16 Derivatives of N-(1H-indazolyl)- and N-(1H-indolyl)-urea as well as related compounds as modulators of the vanilloid-1 receptor (VR1) for the treatment of pain
EP04768514A EP1675587A2 (en) 2003-09-19 2004-09-16 Derivatives of n-(1h-indazolyl)- and n-(1h-indolyl)-urea as well as related compounds as modulators of the vanilloid-1 receptor (vr1) for the treatment of pain
JP2006526691A JP2007505877A (ja) 2003-09-19 2004-09-16 疼痛治療用バニロイド−１受容体（ｖｒ１）モジュレーターとしてのｎ−（１ｈ−インダゾリル）−尿素誘導体及びｎ−（１ｈ−インドリル）−尿素誘導体並びに関連化合物
CNA2004800271826A CN1856304A (zh) 2003-09-19 2004-09-16 调节辣椒素－1受体(vr1)的功能的杂芳族脲类化合物
PCT/GB2004/003968 WO2005028445A2 (en) 2003-09-19 2004-09-16 Derivatives of n-(1h-indazolyl)- and n-(1h-indolyl)-urea as well as related compounds as modulators of the vanilloid-1 receptor (vr1) for the treatment of pain
CA002538454A CA2538454A1 (en) 2003-09-19 2004-09-16 Derivatives of n-(1h-indazolyl)- and n-(1h-indolyl)-urea as well as related compounds as modulators of the vanilloid-1 receptor (vr1) for the treatment of pain

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0322016.7A GB0322016D0 (en) 2003-09-19 2003-09-19 New compounds

Publications (1)

Publication Number Publication Date
GB0322016D0 true GB0322016D0 (en) 2003-10-22

Family

ID=29266326

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0322016.7A Ceased GB0322016D0 (en) 2003-09-19 2003-09-19 New compounds

Country Status (8)

Country Link
US (1) US20070078156A1 (cg-RX-API-DMAC7.html)
EP (1) EP1675587A2 (cg-RX-API-DMAC7.html)
JP (1) JP2007505877A (cg-RX-API-DMAC7.html)
CN (1) CN1856304A (cg-RX-API-DMAC7.html)
AU (1) AU2004274230A1 (cg-RX-API-DMAC7.html)
CA (1) CA2538454A1 (cg-RX-API-DMAC7.html)
GB (1) GB0322016D0 (cg-RX-API-DMAC7.html)
WO (1) WO2005028445A2 (cg-RX-API-DMAC7.html)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
US7417053B2 (en) 2005-04-07 2008-08-26 Teijin Pharma Limited Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof
FR2897061B1 (fr) 2006-02-03 2010-09-03 Sanofi Aventis Derives de n-heteroaryl-carboxamides tricycliques contenant un motif benzimidazole, leur preparation et leur application en therapeutique.
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
MX2008012482A (es) 2006-03-31 2008-10-10 Abbott Lab Compuestos de indazol.
US8519135B2 (en) 2006-07-14 2013-08-27 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2/CCR9
FR2903985B1 (fr) * 2006-07-24 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2904316B1 (fr) 2006-07-31 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique.
EP2054390B1 (en) 2006-08-25 2012-04-11 Abbott Laboratories Indazole derivatives that inhibit trpv1 and uses thereof
WO2008057300A2 (en) * 2006-10-27 2008-05-15 Redpoint Bio Corporation Trpvi antagonists and uses thereof
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
DE102007018149A1 (de) 2007-04-16 2008-10-23 Grünenthal GmbH Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln
WO2008125342A2 (de) * 2007-04-16 2008-10-23 Grünenthal GmbH Vanilloid-rezeptor-liganden und ihre verwendung zur herstellung von arzneimitteln
BRPI0813695B8 (pt) 2007-07-12 2021-05-25 Chemocentryx Inc compostos de heteroaril piridil e fenil benzenossulfonamidas fundidas, composição, método de modular a função de ccr2, usos dos compostos e forma cristalina
ATE516272T1 (de) 2007-09-14 2011-07-15 Ortho Mcneil Janssen Pharm 1,3-disubstituierte 4-(aryl-x-phenyl)-1h-pyridin- 2-one
WO2009033703A1 (en) 2007-09-14 2009-03-19 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones
RS51660B (sr) 2007-09-14 2011-10-31 Ortho-Mcneil-Janssen Pharmaceuticals Inc. 1`,3`-disupstituisani-4-fenil-3,4,5,6-tetrahidro-2h, 1`h-[1,4`] bipiridinil-2`-oni
EP2220083B1 (en) 2007-11-14 2017-07-19 Janssen Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN102036969A (zh) 2008-03-20 2011-04-27 雅培制药有限公司 制造作为trpv1拮抗剂的中枢神经系统药剂的方法
EP2344470B1 (en) 2008-09-02 2013-11-06 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
AU2009304293B2 (en) 2008-10-16 2012-04-26 Addex Pharma S.A. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
JP5690277B2 (ja) 2008-11-28 2015-03-25 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体
US8937060B2 (en) 2009-05-12 2015-01-20 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
KR20120035158A (ko) 2009-05-12 2012-04-13 얀센 파마슈티칼즈, 인코포레이티드 1,２,４?트리아졸로［４,３?ａ］피리딘 유도체 및 ｍＧｌｕＲ２ 수용체의 양성 알로스테릭 조절자로서의 그의 용도
US8648086B2 (en) 2009-08-24 2014-02-11 Ascepion Pharmaceuticals, Inc. 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors
EP2377850A1 (en) * 2010-03-30 2011-10-19 Pharmeste S.r.l. TRPV1 vanilloid receptor antagonists with a bicyclic portion
CN103298809B (zh) 2010-11-08 2016-08-31 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
EP2643320B1 (en) 2010-11-08 2015-03-04 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
CA2814996C (en) 2010-11-08 2019-10-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
US20120115903A1 (en) * 2010-11-10 2012-05-10 Gruenenthal Gmbh Substituted Heteroaromatic Carboxamide and Urea Compounds as Vanilloid Receptor Ligands
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
HRP20191646T1 (hr) 2014-01-21 2019-12-13 Janssen Pharmaceutica Nv Kombinacije koje sadržavaju pozitivne alosteričke modulatore ili ortosteričke agoniste metabotropnog glutamatergičnog receptora podtip 2 i njihova uporaba
CN109999033B (zh) 2014-01-21 2022-12-23 詹森药业有限公司 包括代谢型谷氨酸能受体亚型2的正别构调节物或正位激动剂的组合及其用途
TWI653227B (zh) * 2014-07-11 2019-03-11 美商陶氏農業科學公司 用於製備４－（１－（４－（全氟乙氧基）苯基）－１ｈ－１，２，４－三唑－３－基）苯甲醯疊氮化物之改良方法
GB201511790D0 (en) * 2015-07-06 2015-08-19 Iomet Pharma Ltd Pharmaceutical compound
CN110177549A (zh) 2016-11-23 2019-08-27 坎莫森特里克斯公司 治疗局灶性节段性肾小球硬化的方法
CN110191709A (zh) 2017-01-17 2019-08-30 德州大学系统董事会 可用作吲哚胺2,3-双加氧酶和/或色氨酸双加氧酶抑制剂的化合物
WO2018136887A1 (en) * 2017-01-23 2018-07-26 Tesaro, Inc. Compounds
CN113651820A (zh) * 2017-03-21 2021-11-16 正大天晴药业集团股份有限公司 用于ido和tdo双重抑制剂的脲类化合物
CN111417389A (zh) 2017-10-11 2020-07-14 坎莫森特里克斯公司 Ccr2拮抗剂对局灶性节段性肾小球硬化症的治疗
US10696638B2 (en) * 2017-12-26 2020-06-30 Industrial Technology Research Institute Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same
US11046649B2 (en) 2018-07-17 2021-06-29 Board Of Regents, The University Of Texas System Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
WO2025248032A1 (en) * 2024-05-31 2025-12-04 Syngenta Crop Protection Ag Pesticidally active indazole compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1182202A (en) * 1966-03-23 1970-02-25 Ferrania Spa Photographic Silver Halide Emulsions and Developers containing Indazolone Colour COuplers
US3647819A (en) * 1969-09-19 1972-03-07 Sterling Drug Inc Indazolylphenylureas and indazolyl-phenylthioureas
US3711610A (en) * 1971-06-01 1973-01-16 Sterling Drug Inc Anticoccidiosis method and compositions involving indazolylphenylureas and indazolylphenylthioureas
US5684041A (en) * 1996-02-01 1997-11-04 The Procter & Gamble Company Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
US6093742A (en) * 1997-06-27 2000-07-25 Vertex Pharmaceuticals, Inc. Inhibitors of p38
US7217722B2 (en) * 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
CA2417507A1 (en) * 2000-08-21 2002-02-28 Pacific Corporation Novel thiourea derivatives and the pharmaceutical compositions containing the same
JP2003192587A (ja) * 2001-12-26 2003-07-09 Bayer Ag 尿素誘導体
MXPA04008073A (es) * 2002-02-20 2004-11-26 Abbott Lab Compuestos azabiciclicos fusionados que inhiben el receptor de subtipo 1 (vr1) del receptor de vainilloide.
AU2003226928A1 (en) * 2002-04-09 2003-10-27 7Tm Pharma A/S Novel aminotetraline compounds for use in mch receptor related disorders
US6933311B2 (en) * 2003-02-11 2005-08-23 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Also Published As

Publication number Publication date
JP2007505877A (ja) 2007-03-15
US20070078156A1 (en) 2007-04-05
EP1675587A2 (en) 2006-07-05
WO2005028445A3 (en) 2005-06-02
AU2004274230A1 (en) 2005-03-31
CA2538454A1 (en) 2005-03-31
WO2005028445A2 (en) 2005-03-31
CN1856304A (zh) 2006-11-01

Similar Documents

Publication Publication Date Title
GB0322016D0 (en) New compounds
GB0309781D0 (en) Compounds
EP1592425A4 (en) NOVEL ARYLPIPERAZINYL COMPOUNDS
GB0305559D0 (en) Compounds
GB0328178D0 (en) Compounds
GB0304665D0 (en) Compounds
EP1689403A4 (en) HETEROARYL-hydrazone compounds
GB0305553D0 (en) Compounds
GB0306329D0 (en) Compounds
GB0313914D0 (en) Compounds
GB0323585D0 (en) Compounds
GB0303086D0 (en) New compounds
EP1682514A4 (en) 11-O-METHYLGELDANAMYCIN COMPOUNDS
GB0302512D0 (en) Compounds
GB0304494D0 (en) Compounds
HUP0302440D0 (en) New compounds
GB0330000D0 (en) Compounds
GB0302543D0 (en) Compounds
GB0309326D0 (en) Compounds
GB0329360D0 (en) Compounds
GB0326997D0 (en) Compounds
GB0300298D0 (en) Compounds
GB0301719D0 (en) Compounds
GB0301916D0 (en) Compounds
GB0321877D0 (en) Compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)